Safety and Efficacy of Lonapegsomatropin in Children with Growth Hormone Deficiency: enliGHten Trial 2-Year Results

CONCLUSIONS: Treatment with lonapegsomatropin continued to be safe and well-tolerated, with no new safety signals identified. Children treated with once-weekly lonapegsomatropin showed continued improvement of height SDS through the 2nd year of therapy without excess advancement of bone age.PMID:35428884 | DOI:10.1210/clinem/dgac217

Source: The Journal of Clinical Endocrinology and Metabolism - April 16, 2022 Category: Endocrinology Authors: Aristides K Maniatis Samuel J Casella Ulhas M Nadgir Paul L Hofman Paul Saenger Elena D Chertock Elena M Aghajanova Maria Korpal-Szczyrska Elpis Vlachopapadopoulou Oleg Malievskiy Tetyana Chaychenko Marco Cappa Wenjie Song Meng Mao Per Holse Mygind Alden Source Type: research